Santoni Matteo, Massari Francesco, Rizzo Alessandro, Mollica Veronica, Cimadamore Alessia, Montironi Rodolfo, Battelli Nicola
Oncology Unit, Macerata Hospital, Macerata, Italy.
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia.
Tumori. 2023 Apr;109(2):157-163. doi: 10.1177/03008916221090323. Epub 2022 May 20.
The treatment of castration-sensitive prostate cancer (CSPC) has been revolutionized by the advent of apalutamide and enzalutamide in this setting; however, a direct comparison between these agents is still missing. In the current paper, we performed both Number Needed to Treat (NNT) and Number Needed to Harm (NNH) analyses aimed to compare clinical outcomes in CSPC patients treated with apalutamide or enzalutamide; data from 3323 CSPC patients enrolled in the ARCHES, ENZAMET and TITAN phase III studies were included. According to our results, apalutamide showed better results in terms of overall survival (OS) and safety in patients with CSPC, while better outcomes were observed with enzalutamide in the low-volume subgroup.
在去势敏感性前列腺癌（CSPC）的治疗中，阿帕鲁胺和恩杂鲁胺的出现给这一领域带来了变革；然而，这两种药物之间的直接比较仍然缺失。在当前论文中，我们进行了治疗所需人数（NNT）和伤害所需人数（NNH）分析，旨在比较接受阿帕鲁胺或恩杂鲁胺治疗的CSPC患者的临床结局；纳入了3323名参加ARCHES、ENZAMET和TITAN III期研究的CSPC患者的数据。根据我们的结果，在CSPC患者的总生存期（OS）和安全性方面，阿帕鲁胺显示出更好的结果，而在低瘤负荷亚组中，恩杂鲁胺观察到更好的结局。
